Nektar Therapeutics’ stock didn’t surge as investors may have expected following a jury verdict in its favor versus Eli Lilly over the termination of a rezpegaldesleukin (rezpeg) collaboration. The court awarded Nektar $90 million plus interest, far below the $1 billion sought, but the report notes the win did not force the company to fund pipeline development from the award.